8-K current report · filed Nov 5, 2026

Prestige Consumer Healthcare Inc. (PBH) 8-K Current Report: November 5, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2PBH overview

Short answer

Prestige Consumer Healthcare Inc. (PBH) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Earnings announcement covers fiscal quarter and six months ended September 30, 2026.

Prestige Consumer Healthcare Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Earnings announcement covers fiscal quarter and six months ended September 30, 2026
  • Results press release attached as Exhibit 99.1, providing the substantive financial details

Item 7.01 · Regulation FD Disclosure

  • Investor presentations began November 5, 2026, covering results for the quarter and six months ended September 30, 2026
  • Exhibit 99.2 contains management’s financial-results slides, the primary source for detailed metrics and outlook
  • Presentation materials may be reused or modified through fiscal year ending March 31, 2027

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $336.3M, up 22.7%, but organic revenue declined 1.6% excluding $65.1M from acquisitions
  • Adjusted diluted EPS $1.13, up from $1.07, while GAAP diluted EPS fell to $0.53 from $0.86
  • Breathe Right and LaCorium contributed $65.1M in Q2, with acquisitions performing in line with expectations
  • Fiscal 2027 guidance reduced to $1,280M-$1,290M revenue and $4.48-$4.55 adjusted EPS
  • Clear Eyes supply constraints at Pillar5 expected to reduce second-half product availability and revenue; net debt approximately $2B

Item EX-99.2 · Exhibit EX-99.2

  • Q2 revenue $336.3M, up 22.7%, but organic revenue declined 1.6% due to sales timing
  • Adjusted EBITDA $113.0M, up 30.1%, with margin expanding to 33.6% from 31.7%
  • Adjusted EPS $1.13 versus $1.07, while first-half adjusted EPS reached $2.11, up 4.5%
  • FY27 outlook reduced to revenue $1,280-$1,290M and adjusted EPS $4.48-$4.55
  • Net debt $2.1B, with no maturities until 2031 and adjusted free cash flow target of $265M or more aiding deleveraging

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Prestige Consumer Healthcare Inc. 8-K filings

Get the next PBH 8-K as it lands

Follow PBH for push alerts, or ask the research agent what this filing means.